HomeNewsBusinessStocksWockhardt may move to Rs 2000: SP Tulsian

Wockhardt may move to Rs 2000: SP Tulsian

SP Tulsian of sptulsian.com feels that Wockhardt may move to Rs 2000.

November 17, 2015 / 17:53 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

SP Tulsian of sptulsian.com told CNBC-TV18, "On Dishman Pharma there is some news of API with oncology and all that which cannot be verified and all sort of things, but apart from that if you see stock has doubled from Rs 200 to Rs 400 in last three months. In fact if you see the behaviour or may be the pattern of the investment also, the prudent investor will exit at some point of time. May be these news flows are used as an exit or as a trigger."He further added, "Strides Arcolab has been the most reliable trading stock. It equally bounces back. If it corrects by Rs 100-150 it will quickly bounce back, it does not needs any news flows to really recover and all that. Cadila Healthcare has corrected again on news flows in this last couple of days, fell to a low of sub Rs 400. In fact I am quite positive on Cadila because looking to Q2 numbers and looking to the growth prospects or may be the pipeline ahead I am positive on that but if any adverse news comes in that is going to derail this one.""We have discussed Wockhardt extensively after the numbers, the kind of growth and US has not really started contributing in fact to that whole growth performance which the company has shown except from UK and may be from emerging market, the company has not shown any kind of - once the approval all comes in which again market is eagerly waiting that the event is going to happen in next 2-3 months for their Waluj and Chikalthana plant and that will really be giving a big boost.""Many ANDAs are pending with the USFDA for approval. So, once that process will start, I think ball will start rolling on the USFDA front. Again I gave the target at that time also, I won't be surprised to see a price of Rs 2000 because Q2 numbers were quite good. In fact if you take the overall scenario 13 percent spent on R&D, 17 percent EBITDA, Rs 40 EPS now in the current situation, if the US FDA starts contributing I won't be surprised to see EPS moving to Rs 54-55 may be for FY17. So, taking all this share can move to Rs 2000 may be in next 3-4 months," he said.

first published: Nov 17, 2015 04:59 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!